Clinical trials: Semaglutide, completed
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Nonalcoholic Steatohepatitis
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT03987074
- Testing
- Semaglutide, Firsocostat, Cilofexor
- Where
- 18 sites in United States
- Volunteers
- 109 people
- Sponsor
- Gilead Sciences
Hepatobiliary Disorders, Non-alcoholic Fatty Liver Disease
A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
This study is looking at the effect of semaglutide on subjects with nonalcoholic fatty liver disease.This study is comparing the change in early stages of scar tissue in the liver and fat deposition in the liver in people taking…
- Trial name
- NCT03357380
- Testing
- Semaglutide
- Where
- 2 sites in Germany
- Volunteers
- 67 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability and pharmacokinetics (the effect of the investigated drug on the body) of single and multiple doses of a long-acting GLP-1…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01866748
- Testing
- semaglutide
- Where
- Germany
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
Response to Semaglutide in Non-diabetic Obese Patients With Varying Degrees of Insulin Resistance
Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Insulin Sensitivity/Resistance, Semaglutide
- Trial name
- TRIM-IR (NCT06856291)
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- ETH Zurich
Short Bowel Syndrome (SBS), Intestinal Failure
Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.
Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention.
- Trial name
- NCT07297238
- Testing
- GLP-1 Receptor Agonists
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Jinling Hospital, China
Type 2 Diabetes, Heart Failure
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07390110
- Testing
- Oral semaglutide, Sitagliptin
- Where
- United States
- Volunteers
- 25,664 people
- Sponsor
- Brigham and Women's Hospital
Diabetes, Diabetes Mellitus, Type 2
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability after a single injection of semaglutide in subjects with mild…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Hepatic Impaired
- Trial name
- NCT02210871
- Testing
- semaglutide
- Where
- 4 sites in Poland, Slovakia
- Volunteers
- 44 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers Type 2 Diabetes
A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men
This study looks at how the new medicine called NNC0480-0389 works in the body of Japanese men when it is given together with semaglutide.
- Trial name
- NCT04878406
- Testing
- NNC0480-0389, Semaglutide
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity or Overweight
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide.
- Trial name
- REDEFINE 6 (NCT05996848)
- Testing
- Cagrilintide, Semaglutide
- Where
- 37 sites in China
- Volunteers
- 300 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorders, Overweight or Obesity
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body.
- Trial name
- NCT03574584
- Testing
- NNC0165-1562, Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Novo Nordisk A/S
Obese Diabetics, Obese Non Diabetic
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
titel : Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Abstract : Background: This study that highlights the different effects of most used three GLP-RA…
- Trial name
- NCT07820111
- Testing
- Dulaglutide 1.5 MG/ML, Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician
- Where
- Saudi Arabia
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Psoriasis Vulgaris, Diabetes Type 2
Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus
The use of semaglutide in patients with DMT2 and psoriasis contributes to improving the clinical picture of psoriasis and reducing the inflammatory response
- Trial name
- NCT06475586
- Testing
- Semaglutide
- Where
- Bosnia and Herzegovina
- Volunteers
- 30 people
- Sponsor
- University of Banja Luka
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic drug) in Japanese subjects with type 2…
- Trial name
- PIONEER 10 (NCT03015220)
- Testing
- Semaglutide, Dulaglutide
- Where
- 34 sites in Japan
- Volunteers
- 458 people
- Sponsor
- Novo Nordisk A/S
PCOS, Semaglutide
The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity
The purpose of the study is to explore the effects of GLP-1 receptor agonist (GLP-1 RA) semaglutide on modulation of taste sensitivity, tongue tissue transcriptome, modulation of neural response in central reward processing…
- Conditions
- PCOS, Semaglutide, Taste, Altered, Tongue Tissue Transcriptome
- Trial name
- NCT04263415
- Testing
- Semaglutide
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Diabetes Mellitus, Type 2
A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
The study will look at how insulin 287 and semaglutide work in the body, both when given alone or together. This study will look at the way insulin 287 and semaglutide reach and stay in participants' blood after injection when…
- Trial name
- NCT03789578
- Testing
- NNC0148-0287sema, Semaglutide, NNC0148-0287
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Obesity or Overweight
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week.
- Trial name
- NCT05813925
- Testing
- Cagrilintide, Semaglutide
- Where
- 28 sites in Japan, Taiwan
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo.
- Trial name
- NCT06797869
- Testing
- CagriSema (Cagrilintide B and Semaglutide I)
- Where
- 55 sites in United States, Canada and 5 more
- Volunteers
- 142 people
- Sponsor
- Novo Nordisk A/S
Obesity, Aging
Semaglutide Use in Elderly Obese Patients
This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly…
- Trial name
- NCT05302596
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Obesity
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
This is a multicenter, randomized, open, parallel, positive-controlled clinical study to evaluate the efficacy and safety of Semaglutide injection (TQF3510) developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Trial name
- NCT06738979
- Testing
- TQF3510 (Semaglutide Injection), Wegovy®
- Where
- 66 sites in China
- Volunteers
- 408 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.